We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+20.65%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$6.54M
(+2%)
Cap. Flow
+$45.9M
Cap. Flow
% of AUM
13.92%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
104
New
22
Increased
33
Reduced
18
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$17.8M |
| 2 |
UroGen Pharma
URGN
|
+$8.17M |
| 3 |
MRSN
Mersana Therapeutics
MRSN
|
+$7.61M |
| 4 |
Gossamer Bio
GOSS
|
+$7.06M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schrodinger
SDGR
|
+$10.3M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$10.2M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$9.78M |
| 4 |
Krystal Biotech
KRYS
|
+$5.78M |
| 5 |
ETNB
89bio
ETNB
|
+$5.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.31% |
| 2 | Consumer Staples | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Veracyte
VCYT
$4.45B
| $5.35M | 1.62% |
239,571
+10,120
| +4% | +$260K |
|
|
KALV
27
CALL
DELISTED
KalVista Pharmaceuticals
KALV
| $5.11M | 1.55% |
+530,400
| New | +$5.42M |
|
|
28
Gossamer Bio
GOSS
$101M
| $5.11M | 1.55% |
+6,130,268
| New | +$7.06M |
|
29
Olema Pharmaceuticals
OLMA
$977M
| $5.04M | 1.53% |
407,801
+17,335
| +4% | +$177K |
|
30
Humana
HUM
$43.9B
| $4.87M | 1.48% |
+10,000
| New | +$4.7M |
|
31
Vertex Pharmaceuticals
VRTX
$123B
| $4.79M | 1.45% |
13,765
+590
| +4% | +$206K |
|
32
Gilead Sciences
GILD
$165B
| $4.71M | 1.43% |
62,789
+2,341
| +4% | +$180K |
|
33
Pliant Therapeutics
PLRX
$65M
| $4.34M | 1.32% |
250,409
+143,142
| +133% | +$2.48M |
|
34
Caribou Biosciences
CRBU
$146M
| $4.27M | 1.29% |
+892,786
| New | +$5.54M |
|
|
IMGN
35
CALL
DELISTED
Immunogen Inc
IMGN
| $3.97M | 1.2% |
+250,000
| New | +$4.16M |
|
36
TELA Bio
TELA
$30.3M
| $3.92M | 1.19% |
490,471
+74,031
| +18% | +$688K |
|
37
Insmed
INSM
$22.4B
| $3.8M | 1.15% |
150,387
+5,923
| +4% | +$135K |
|
38
Mirum Pharmaceuticals
MIRM
$6.56B
| $3.48M | 1.06% |
110,114
+3,739
| +4% | +$102K |
|
|
CBAY
39
CALL
DELISTED
Cymabay Therapeutics
CBAY
| $2.98M | 0.9% |
+200,000
| New | +$2.65M |
|
|
RVPH
40
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $2.75M | 0.83% |
+28,200
| New | +$2.63M |
|
41
Zura Bio
ZURA
$504M
| $2.67M | 0.81% |
404,040
+244,040
| +153% | +$1.63M |
|
|
TERN
42
DELISTED
Terns Pharmaceuticals
TERN
| $2.52M | 0.76% |
500,000
-99,668
| -17% | -$632K |
|
|
MTEM
43
DELISTED
Molecular Templates, Inc.
MTEM
| $2.24M | 0.68% |
+354,608
| New | +$2.82M |
|
|
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
| $2.2M | 0.67% |
228,934
-491,574
| -68% | -$5.02M |
|
45
Trevi Therapeutics
TRVI
$2.57B
| $2.02M | 0.61% |
927,415
+41,491
| +5% | +$93.7K |
|
46
Kodiak Sciences
KOD
$2.5B
| $2.01M | 0.61% |
+1,114,461
| New | +$3.93M |
|
47
Cerus
CERS
$575M
| $1.95M | 0.59% |
1,203,890
+45,625
| +4% | +$94.8K |
|
48
Xenon Pharmaceuticals
XENE
$6.1B
| $1.84M | 0.56% |
53,996
-45,760
| -46% | -$1.71M |
|
49
Evogene
EVGN
$5.83M
| $1.82M | 0.55% |
310,000
+300,000
| +3,000% | +$2.63M |
|
50
Intellia Therapeutics
NTLA
$1.51B
| $1.68M | 0.51% |
53,018
+2,160
| +4% | +$83.8K |
|
Similar funds
BIP
MVM
MFWP
FCM
PE
KL
GFP
ADIC
Silverarc Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, Silverarc Capital Management held 104 positions worth $330M, up 2% from $323M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Silverarc Capital Management deployed $45.9M of net new capital in Q3 2023, opening 22 new positions and adding to 33 existing holdings. Its largest new stake was UroGen Pharma: 508,883 shares worth $7.13M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Consumer Staples.
On the sell side, the largest reduction was Schrodinger, an estimated $10.3M trimmed.
- Silverarc Capital Management's largest Q3 2023 buy was UroGen Pharma: 508,883 shares worth $7.13M.
- Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q3 2023, an estimated $17.8M increase.
- Silverarc Capital Management's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $10.3M.
- Silverarc Capital Management fully exited MoonLake Immunotherapeutics in Q3 2023, selling an estimated $10.2M.
- Silverarc Capital Management's ten largest holdings make up 38% of its $330M portfolio in Q3 2023.
- Silverarc Capital Management opened 22 new positions and closed 24 in Q3 2023.
- Silverarc Capital Management's portfolio value rose 2% quarter-over-quarter to $330M.
Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.